Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review

Author(s): Ron Batash, Noam Asna*, Pamela Schaffer, Nicole Francis, Moshe Schaffer

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 27 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.

Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.

Method: Systemic compilation of the relevant literature.

Results & Conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.

Keywords: Biologic agent, chemotherapy, glioblastoma multiforme, immunotherapy, radiation therapy, vaccination.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 16 May, 2017
Page: [3002 - 3009]
Pages: 8
DOI: 10.2174/0929867324666170516123206
Price: $65

Article Metrics

PDF: 316
HTML: 214
PRC: 9